Global Immunomodulator Market Projected to Nearly Double, Reaching $477.55 Billion by 2034 - Evolution of Immunomodulatory Treatments for Cancer Creating Lucrative Opportunities for Oncolo...
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
In a significant development for the healthcare industry, the global immunomodulator market is poised for substantial growth, anticipated to soar from USD 233.03 billion in 2023 to USD 477.55 billion by 2034. This remarkable expansion is forecasted at a robust Compound Annual Growth Rate (CAGR) of 6.74% during the period from 2024 to 2034. This upsurge is attributed to the escalating prevalence of immunological disorders, increased research and development activities, enhanced patient preference for biologic therapies, and continuous advancements in drug development technologies. Product Innovation and Mergers The notable upswing in the market is largely driven by the immunosuppressants segment, which commanded the highest revenue in 2023. Their established efficacy in preventing organ transplant rejection and managing autoimmune diseases has reinforced demand. Furthermore, a series of strategic acquisitions by major pharmaceutical players has underpinned this sector, exemplified
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Coherus offloads Humira biosimilar Yusimry for $40m [Yahoo! Finance]Yahoo! Finance
- Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at Argus from $300.00 to $340.00. They now have a "buy" rating on the stock.MarketBeat
- Comprehensive Diabetic Neuropathy Pipeline Insight Report for 2024 Reveals Progress in Treatment Landscape [Yahoo! Finance]Yahoo! Finance
- Global Pharmaceutical Marketing Industry Research Report 2024-2030: Market Size Projections for Conference Marketing, PPC Advertising, Print Advertising, Social Media Campaigns, TV Commercials, and More [Yahoo! Finance]Yahoo! Finance
- Why Amgen (AMGN) Outpaced the Stock Market Today [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 5/2/24 - Beat
AMGN
Sec Filings
- 6/21/24 - Form 11-K
- 6/21/24 - Form 11-K
- 6/12/24 - Form S-8
- AMGN's page on the SEC website